Articles
Scientist gets his mind around Alzheimer’s
It’s not known what causes the disease or how to cure it. And the stakes have never been higher. But one European neuroscientist is leading the charge to uncover new treatments for this neurodegenerative disease. The...
Drug Research
Lycera Announces Research Collaboration with Merck
Lycera Corporation, a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, announced that it has entered into an exclusive research collaboration with Merck to discover, develop and commercialize small molecules that target T-helper...
Drug Research
Shire Strengthens Specialty Pharmaceuticals Team with Senior R&D Appointments
Shire plc, the global specialty biopharmaceutical company, today announced the appointment of two senior Research & Development executives to its Specialty Pharmaceuticals business. Lawson Macartney, DVM, PhD, FRCPath, has been appointed Senior Vice President of the Emerging Business Unit...
Articles
Maximising Drug Discovery Research
Interview with: Teodor Aastrup, Chief Executive Officer, Attana AB "Drug discovery scientists should focus on the biological relevance of their candidate molecules as soon as possible in their research, to ensure a high probability of success...
Drug Research
King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for REMOXY
King Pharmaceuticals®, Inc. and Pain Therapeutics®, Inc. announced that King has resubmitted a New Drug Application (NDA) for REMOXY® (oxycodone) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response letter received by Pain Therapeutics...
Drug Research
King Pharmaceuticals and Acura Pharmaceuticals Announce Submission of New Drug Application for ACUROX Tablets
King Pharmaceuticals®, Inc. and Acura Pharmaceuticals, Inc. announced that King has submitted a New Drug Application (NDA) for ACUROX® (oxycodone HCl) Tablets to the U.S. Food and Drug Administration (FDA), including a request for priority review classification. ACUROX® is...
Drug Research
Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib
Pfizer Inc. announced that a significantly higher proportion of patients with newly diagnosed chronic myeloid leukemia who were treated with bosutinib (39 percent) experienced a major molecular response (MMR), a secondary endpoint, compared with patients treated with imatinib (26...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
